|
Amyotrophic Lateral Sclerosis |
Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis |
$10,857,762 |
3- FDA filing |
|
Amyotrophic Lateral Sclerosis |
Progenitor Cells Secreting GDNF for the Treatment of ALS |
$17,842,617 |
4- Early phase clinical trials |
|
Amyotrophic Lateral Sclerosis |
Molecules to Correct Aberrant RNA Signature in Human Diseased Neurons |
$1,654,830 |
1- Proof of concept |
|
Heart Disease |
Identification of Novel Therapeutics for Danon Disease Using an iPS Model of the Disease |
$1,701,575 |
1- Proof of concept |
|
Heart Disease |
Direct Cardiac Reprogramming for Heart Regeneration |
$6,319,110 |
2- Development candidate |
|
Heart Disease |
Human ES cell based therapy of heart failure without allogenic immune rejection |
$1,857,600 |
1- Proof of concept |
|
Heart Disease |
Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction |
$19,782,136 |
4- Early phase clinical trials |
|
Heart Disease |
Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$19,999,899 |
3- FDA filing |
|
Heart Disease |
Direct reprogramming towards vascular progenitors for the treatment of ischemia |
$2,340,000 |
1- Proof of concept |
|
Heart Disease |
Heart Repair with Human Tissue Engineered Myocardium |
$4,766,231 |
2- Development candidate |
|
Heart Disease |
Extracellular Matrix Bioscaffold Augmented with Human Stem Cells for Cardiovascular Repair |
$4,939,140 |
2- Development candidate |
|
Heart Disease |
Autologous cardiac-derived cells for advanced ischemic cardiomyopathy |
$5,560,232 |
3- FDA filing |
|
Alzheimer's disease |
Restoration of memory in Alzheimer’s disease: a new paradigm using neural stem cell therapy |
$20,000,000 |
3- FDA filing |
|
Alzheimer's disease |
Identifying Drugs for Alzheimer's Disease with Human Neurons Made From Human IPS cells |
$1,857,600 |
1- Proof of concept |
|
Alzheimer's disease |
Stem cell based small molecule therapy for Alzheimer's disease |
$1,673,757 |
1- Proof of concept |
|
Alzheimer's disease |
Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease |
$3,599,997 |
2- Development candidate |
|
Arthritis |
Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis |
$6,792,660 |
2- Development candidate |
|
Arthritis |
Stem Cell-Based Therapy for Cartilage Regeneration and Osteoarthritis |
$3,118,431 |
2- Development candidate |
|
Blood Disorders |
Stem Cell Gene Therapy for Sickle Cell Disease |
$9,212,365 |
3- FDA filing |
|
Blood Disorders |
A Phase 1/2, Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects with β-Thalassemia by Transplantation of Autologous Hematopoietic Stem Cells [REDACTED] |
$9,363,335 |
4- Early phase clinical trials |
|
Bone or Cartilage Disease |
Treatment of osteoporosis with endogenous Mesenchymal stem cells |
$19,999,867 |
4- Early phase clinical trials |
|
Bone or Cartilage Disease |
Harnessing native fat-residing stem cells for bone regeneration |
$5,391,560 |
2- Development candidate |
|
Bone or Cartilage Disease |
Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures |
$1,927,698 |
1- Proof of concept |
|
Bone or Cartilage Disease |
Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells |
$1,735,703 |
1- Proof of concept |
|
Bone or Cartilage Disease |
Enhancing healing via Wnt-protein mediated activation of endogenous stem cells |
$5,767,050 |
2- Development candidate |
|
Blood cancer |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$3,607,305 |
2- Development candidate |
|
Blood cancer |
Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) |
$19,999,826 |
3- FDA filing |
|
Blood cancer |
Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells |
$19,999,996 |
3- FDA filing |
|
Blood cancer |
Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy |
$3,341,758 |
2- Development candidate |
|
Brain cancer |
Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials |
$18,015,429 |
3- FDA filing |
|
Brain cancer |
Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells |
$5,217,004 |
2- Development candidate |
|
Brain cancer |
Stem cell-based carriers for RCR vector delivery to glioblastoma |
$3,370,607 |
2- Development candidate |
|
Melanoma |
Genetic Re-programming of Stem Cells to Fight Cancer |
$19,999,563 |
4- Early phase clinical trials |
|
Solid Tumor |
THERAPEUTIC OPPORTUNITIES TO TARGET TUMOR INITIATING CELLS IN SOLID TUMORS |
$19,979,660 |
3- FDA filing |
|
Diabetes |
Cell Therapy for Diabetes |
$22,999,937 |
3- FDA filing |
|
Diabetes |
Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes |
$10,075,070 |
4- Early phase clinical trials |
|
HIV/AIDS |
ZIinc Finger Nuclease-Based Stem Cell Therapy for AIDS |
$14,583,187 |
3- FDA filing |
|
HIV/AIDS |
Development of RNA-based approaches to stem cell gene therapy for HIV |
$3,124,130 |
2- Development candidate |
|
HIV/AIDS |
HPSC based therapy for HIV disease using RNAi to CCR5. |
$9,905,604 |
3- FDA filing |
|
Immune Disease |
Curing Hematological Diseases |
$6,649,347 |
2- Development candidate |
|
Immune Disease |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$20,000,000 |
4- Early phase clinical trials |
|
Immune Disease |
Gene Correction of Autologous Hematopoietic Stem Cells in Artemis Deficient SCID |
$3,931,662 |
2- Development candidate |
|
Liver Disease |
Generation of safe and therapeutically effective human induced hepatocyte-like cells |
$1,544,170 |
1- Proof of concept |
|
Liver Disease |
Liver Cell Transplantation |
$5,199,767 |
2- Development candidate |
|
Liver Disease |
Generation of hepatic cell from placental stem cell for congenital metabolic disorders |
$1,750,375 |
1- Proof of concept |
|
Muscular Dystrophy |
Stem Cell Therapy for Duchenne Muscular Dystrophy |
$2,325,933 |
1- Proof of concept |
|
Autism |
Developing a drug-screening system for Autism Spectrum Disorders using human neurons |
$1,491,471 |
1- Proof of concept |
|
Huntington's Disease |
MSC engineered to produce BDNF for the treatment of Huntington's disease |
$18,950,061 |
4- Early phase clinical trials |
|
Huntington's Disease |
Sustained siRNA production from human MSC to treat Huntingtons Disease and other neurodegenerative disorders |
$2,753,559 |
2- Development candidate |
|
Huntington's Disease |
A hESc-based Development Candidate for Huntington's Disease |
$3,799,817 |
2- Development candidate |
|
Multiple Sclerosis |
Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis |
$4,327,175 |
2- Development candidate |
|
Multiple Sclerosis |
Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells |
$4,799,814 |
2- Development candidate |
|
Parkinson's disease |
Developmental Candidates for Cell-Based Therapies for Parkinson's Disease (PD) |
$5,416,003 |
2- Development candidate |
|
Parkinson's disease |
Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model |
$2,472,839 |
1- Proof of concept |
|
Parkinson's disease |
Banking transplant ready dopaminergic neurons using a scalable process |
$6,016,624 |
2- Development candidate |
|
Spinal Muscular Atrophy |
New Drug Discovery for SMA using Patient-derived Induced Pluripotent Stem Cells |
$5,665,887 |
2- Development candidate |
|
Spinal Cord Injury |
Functional Neural Relay Formation by Human Neural Stem Cell Grafting in Spinal Cord Injury |
$4,699,569 |
2- Development candidate |
|
Spinal Cord Injury |
Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons |
$1,614,441 |
1- Proof of concept |
|
Spinal Cord Injury |
Neural stem cell transplantation for chronic cervical spinal cord injury |
$20,000,000 |
3- FDA filing |
|
Spinal Cord Injury |
Human ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury |
$1,623,251 |
1- Proof of concept |
|
Stroke |
Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke |
$20,000,000 |
3- FDA filing |
|
Pediatrics |
Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease |
$5,509,978 |
2- Development candidate |
|
Skeletal Muscle |
Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients |
$1,825,920 |
1- Proof of concept |
|
Skin Disease |
Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds |
$4,526,900 |
2- Development candidate |
|
Skin Disease |
iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa |
$11,709,574 |
3- FDA filing |
|
Trauma |
Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury |
$1,708,549 |
1- Proof of concept |
|
Vision Loss |
Retinal progenitor cells for treatment of retinitis pigmentosa |
$17,306,668 |
4- Early phase clinical trials |
|
Vision Loss |
Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration |
$5,945,738 |
2- Development candidate |
|
Vision Loss |
Regeneration of Functional Human Corneal Epithelial Progenitor Cells |
$1,654,058 |
1- Proof of concept |
|
Vision Loss |
Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration |
$5,503,069 |
2- Development candidate |
|
Vision Loss |
Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$18,904,916 |
3- FDA filing |
|
Vision Loss |
Human retinal progenitor cells as candidate therapy for retinitis pigmentosa |
$4,738,251 |
2- Development candidate |
|
Epilepsy |
Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy |
$1,752,058 |
1- Proof of concept |
|
Canavan disease |
Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell |
$1,731,750 |
1- Proof of concept |
|
Vascular disease |
Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia |
$14,184,595 |
4- Early phase clinical trials |
|
Incontinence |
Autologous iPSC Therapy for Urinary Incontinence |
$5,279,607 |
2- Development candidate |
